Stockwatch: as pharma becomes the new biotech
This article was originally published in Scrip
Executive Summary
This week's explosion of second quarter earnings announcements thrust separate themes onto investors in pharmaceutical and biotechnology stocks. Some of those themes, like the patent cliff, have been a long time coming, some, like good second quarter earnings, seem to happen about the same time every year, and some may be a shorter-term cyclical effect.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.